Andrew Dhawan

Oct 9, 2023 | frontiersin.org | James Chow |Andrew Dhawan |Arun Radhakrishnan

1 IntroductionMore than 50% of all cancer patients will receive radiation therapy (RT) during the course of their cancer treatment, either given with curative intent as a single agent, concurrently with systemic therapies, or (neo-)adjuvant to other therapeutic approaches, or in the palliative setting (1). Even modest improvements in treatment outcomes and quality of life for cancer patients undergoing RT would yield benefits for a large patient cohort.